EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Intensified multifactorial intervention leads to long‐term benefit on kidney outcomes in advanced diabetic kidney disease: A 10‐year follow‐up of the DNETT ‐Japan trial

Kenichi Shikata, Satoshi Miyamoto iD, Masakazu Haneda, Hiroki Hosoi, Kota Sakamoto, Yoshiki Suzuki, Daisuke Suzuki, Hitoshi Ishida, Hiroaki Akai, Yasuhiko Tomino, Takashi Uzu iD, Motonobu Nishimura und 6 weitere

Journal of Diabetes Investigation · 2026

DOI: 10.1111/jdi.70392 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Diabetes Investigation, 2026. Verfasst von Kenichi Shikata und 17 weiteren Autor:innen. Beteiligte Einrichtung: Okayama University, Okayama, Japan. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Type 2, Kidney Failure, Chronic. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Ministry of Health, Labour and Welfare of Japan, Asahi Kasei Pharma, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Despite recent therapeutic advances in slowing kidney disease progression, the long‐term efficacy of intensive multifactorial treatment in advanced‐stage diabetic kidney disease remains unclear. We assessed long‐term kidney outcomes through the 5‐year Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan) and an additional 5‐year post‐trial observational follow‐up. Materials and Methods A total of 164 patients with advanced‐stage diabetic kidney disease (urinary albumin‐to‐creatinine ratio ≥ 300 mg/g and serum creatinine 1.2–2.5 mg/dL in men and 1.0–2.5 mg/dL in women) were randomly assigned to intensive multifactorial treatment—targeting glycemic, blood pressure, and lipid control with lifestyle modification—or conventional treatment for 5 years. After the intervention, an additional 5‐year observational follow‐up was conducted. The primary outcome was the composite of a doubling of serum creatinine, end‐stage kidney disease, or all‐cause death.

Results

Forty‐four patients who were free of the primary outcome during the intervention entered the follow‐up study. The risk of the primary outcome was lower in the intensive multifactorial treatment group versus the conventional treatment group (hazard ratio, 0.62; 95% confidence interval, 0.41–0.93; P = 0.021). Increases in systolic blood pressure (per 10 mmHg) and serum low‐density lipoprotein cholesterol (per 10 mg/dL) during the intervention were associated with a higher risk of the primary outcome (hazard ratio, 1.43 [1.15–1.78] and 1.23 [1.12–1.35], respectively).

Discussion

The benefit of 5‐year intensive multifactorial treatment on kidney outcomes was demonstrated during an additional 5‐year follow‐up period, highlighting the importance of sustained comprehensive risk‐factor management in advanced‐stage diabetic kidney disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesDiabetes Mellitus, Type 2Kidney Failure, ChronicHumansMaleFemaleFollow-Up StudiesMiddle AgedDisease ProgressionJapanAgedTreatment OutcomeCreatinineBlood PressurePrognosis

Stichwörter der Autor:innen

DNETT‐Japandiabetic kidney diseaseintensive multifactorial treatment

Substanzen

Creatinine

Autor:innen und Institutionen

  • Okayama University, Okayama, Japan.
  • Center for Innovative Clinical Medicine, Medical Development Field, Okayama University, Okayama, Japan.
  • Asahikawa Medical University, Asahikawa, Japan.
  • Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Division of Clinical Nephrology and Rheumatology, Niigata University Medical and Dental Hospital, Niigata, Japan.
  • Suzuki Diabetes Clinic, Atsugi, Japan.

ORCID-Profile: Satoshi Miyamoto, Takashi Uzu

Förderung

  • the Ministry of Health, Labour and Welfare of Japan
  • Asahi Kasei Pharma
  • AstraZeneca
  • Otsuka
  • Kowa Pharmaceutical
  • Daiichi Sankyo
  • Sanwa Kagaku
  • Sanofi Aventis

Zitieren

APA

Shikata, K., Miyamoto, S., Haneda, M., Hosoi, H., Sakamoto, K., Suzuki, Y., Suzuki, D., Ishida, H., Akai, H., Tomino, Y., Uzu, T., Nishimura, M., Kuramoto, H., Yoshida, M., Ogawa, D., Ninomiya, T., Makino, H., & Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan) collaborative group (2026). Intensified multifactorial intervention leads to long‐term benefit on kidney outcomes in advanced diabetic kidney disease: A 10‐year follow‐up of the DNETT ‐Japan trial. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70392

Vancouver

Shikata K, Miyamoto S, Haneda M, Hosoi H, Sakamoto K, Suzuki Y, et al. Intensified multifactorial intervention leads to long‐term benefit on kidney outcomes in advanced diabetic kidney disease: A 10‐year follow‐up of the DNETT ‐Japan trial. Journal of Diabetes Investigation. 2026. doi:10.1111/jdi.70392

BibTeX
@article{Shikata2026,
  author = {Shikata, Kenichi and Miyamoto, Satoshi and Haneda, Masakazu and Hosoi, Hiroki and Sakamoto, Kota and Suzuki, Yoshiki and Suzuki, Daisuke and Ishida, Hitoshi and Akai, Hiroaki and Tomino, Yasuhiko and Uzu, Takashi and Nishimura, Motonobu and Kuramoto, Hiromi and Yoshida, Michihiro and Ogawa, Daisuke and Ninomiya, Toshiharu and Makino, Hirofumi and Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan) collaborative group, Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan) collaborative group},
  title = {Intensified multifactorial intervention leads to long‐term benefit on kidney outcomes in advanced diabetic kidney disease: A 10‐year follow‐up of the DNETT ‐Japan trial},
  journal = {Journal of Diabetes Investigation},
  year = {2026},
  doi = {10.1111/jdi.70392}
}
Kostenlos starten →